Diagnosis and treatment of arterial hypertension in chronic kidney disease


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Авторлар туралы

I Kutyrina

M Shvetsov

V Fomin

M Shestakova

A Shutov

A Tsygin

Әдебиет тізімі

  1. Александров А.А., Кисляк О.А., Леонтьева И.В., Розанов В.Б. Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Кардиоваскулярная терапия и профилактика. 2009; 8(4): 253-288.
  2. Багдасарян А.Р., Столяревич Е.С., Ким И.Г., Суханов А.В., Бирюкова Л.С., Ильинский И.М., Томилина Н.А. Влияние эналаприла на скорость прогрессирования хронической трансплантационной нефропатии. Нефрология и диализ. 2003; 5(1): 42-47.
  3. Боровкова Н.Ю. Артериальная гипертензия при хроническом гломерулонефрите. Вопросы патогенеза. Терапия. Ниж. Новгород, 2012.
  4. Ветчинникова О.Н., Агальцов М.В., Пронина В.П., Кулаков Н.В., Федорова С.И., Ватазин А.В., Молчанова Г.С. Особенности течения синдрома артериальной гипертензии у больных хронической почечной недостаточностью на перитонеальном диализе. Нефрология и диализ. 2006; 8(2): 158-163.
  5. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-й выпуск. Сахарный диабет. 18 (1S) : 1-112. 2015.
  6. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. Руководство для врачей. Медицинское информационное агентство, 2006.
  7. Добронравов В.А., Волков М.М., Смирнов А.В., Рожинская Л.Я., Ермоленко В.М., Шостка Г.Д. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Нефрология и диализ. 2011; 13(1): 33-51.
  8. Карабаева А.Ж., Каюков И.Г., Смирнов А.В., Есаян A.M. Ренинангиотензин-альдостероновая система при хронической болезни почек. Нефрология. 2006; 10(4): 43-48.
  9. Кутырина И.М., Балкаров И.М., Швецов М.Ю., Козловская Н.Л., Моисеев С.В., Шилов Е.М., Фомин В.В., Зайцев А.Ю., Таронишвили О.И. Ишемическая болезнь почек и сочетанные хронические нефропатии: клинические и прогностические особенности. Терапевтический архив. 2007; 6: 44-49.
  10. Кутырина И.М., Фомин В.В., Швецов М.Ю. Артериальная гипертензия как фактор прогрессирования хронических заболеваний почек. Нефрология национальное руководство. Под ред. Н.А. Мухина. М., ГЭОТАР-Медиа, 2009.
  11. Кутырина И., Мартынов С., Швецов М. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения. Терапевтический архив. 2004; 9: 10-15.
  12. Мартынов С., Швецов М., Кутырина И. Нарушения суточного ритма артериального давления у больных хроническим гломерулонефритом. Терапевтический архив. 2006; 1: 23-27. 13.
  13. Методические рекомендации. Под ред. С.А. Бойцова и А.Г. Чучалина. Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. М., 2014.
  14. Мухин Н.А., Фомин В.В., Моисеев С.В., Швецов М.Ю. Нефрогенная артериальная гипертония: эволюция лечения. Терапевтический архив. 2005; 8: 70-78.
  15. Нагайцева С.С., Швецов М.Ю., Герасимов А.Н., Журавлева Е.А., Шилов Е.М. Исследование альбуминурии как маркера хронической болезни почек у взрослого трудоспособного населения. Альманах клинической медицины. 2014; 30: 37-45. 16.
  16. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. под ред. А.В. Смирнова. Нефрология. 2012; 16(1): 15-89. 17.
  17. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Под ред. В.С. Моисеева и Н.А. Мухина. Клиническая нефрология. 2014; 2: 4-29.
  18. Николаев А.Ю. Особенности диализной гипертонии. Нефрология. 2000; 1: 96-98.
  19. Серов В.А., Шутов A.M., Серова Д.В., Шевченко С.В., Шмелькова Е.Ю. Особенности суточного профиля артериального давления у больных хроническим кардиоренальным синдромом. Артериальная гипертензия. 2014; 20(6): 538-545.
  20. Тареева И.Е., Швецов М.Ю., Краснова Т.Н., Кутырина И.М., Насонов Е.Л., Кабаенкова Г.С., Федорова Е.Ю., Шилов Е.М. Артериальная гипертония при волчаночном нефрите. Терапевтический архив. 1997; 69(6): 13-17.
  21. Цыгин А.Н. Артериальная гипертензия и ее лечение у детей с заболеваниями почек. Педиатрическая фармакология. 2003; 1(1): 71-74.
  22. Чазова И.Е., Недогода С.В., Жернакова Ю.В., Сусеков А.В., Медведева И.В., Шестакова М.В. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестник. 2014; 20(12): 3-57.
  23. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-26.
  24. Шамхалова М.Ш., Клефортова И.И., Шестакова М.В., Ремизов О.В., Бухман А.И., Алпенидзе В.А., Дедов И.И. Стеноз почечных артерий у больных сахарным диабетом 2-го типа: клиника, диагностика, прогностическая значимость. Терапевтический архив. 2010; 6: 15-21.
  25. Acelajado M.C., Calhoun D.A. Resistant hypertension: who and how to evaluate. Curr. Opin. Cardiol. 2009; 24(4): 340-344.
  26. Agarwal R., Andersen M.J. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006; 69(7): 1175-1180.
  27. Agarwal R., Peixoto A.J., Santos S.F.F., Zoccali C. Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press. Monit. 2009; 14(1): 2-11.
  28. Ahn J.H., Hong H.C., Cho M.J., Kim Y.J., Choi H.Y., Eun C.R., Yang S.J., Yoo H.J., Kim H.Y., Seo J. a, Kim S.G., Choi K.M., Baik S.H., Choi D.S., Kim N.H. Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. Diabetes Metab. J. 2012; 36(2): 128-135.
  29. Appel L.J., Wright J.T., Greene T., Agodoa L.Y., Astor B.C., Bakris G.L., Cleveland W.H., Charleston J., Contreras G., Faulkner M.L., Gabbai F.B., Gassman J.J., Hebert L.A., Jamerson K.A., Kopple J.D., Kusek J.W., Lash J.P., Lea J.P., Lewis J.B., Lipkowitz M.S., Massry S.G., Miller E.R., Norris K., Phillips R.A., Pogue V.A., Randall O.S., Rostand S.G., Smogorzewski M.J., Toto R.D., Wang X. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 2010; 363(10): 918-929.
  30. Arguedas J.A., Leiva V., Wright J.M. Blood pressure targetsfor hypertension in people with diabetes mellitus. Cochrane database Syst. Rev. 2013; 10: CD008277.
  31. Arulkumaran N., Diwakar R., Tahir Z., Mohamed M., Kaski J.C., Banerjee D. Pulse pressure and progression of chronic kidney disease. J. Nephrol. 2010; 23(2): 189-193.
  32. Bakris G.L., Ruilope L., Locatelli F., Ptaszynska a, Pieske B., de Champlain J., Weber M., Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007; 72(7): 879-885.
  33. Bakris G.L., Sarafidis P.A., Weir M.R., Dahlöf B., Pitt B., Jamerson K., Velazquez E.J., Staikos-ByrneL., Kelly R.Y., Shi V., Chiang Y.-T., Weber M.A. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375(9721): 1173-1181.
  34. Bangash F., Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin. J. Am. Soc. Nephrol. 2009; 4(3): 656-664.
  35. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., Stoyanovsky V., Antikainen R.L., Nikitin Y., Anderson C., Belhani A., Forette F., Rajkumar C., Thijs L., Banya W., Bulpitt C.J. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-1898.
  36. Bell E.K., Gao L., Judd S., Glasser S.P., McClellan W., Gutiérrez O.M., Safford M., Lackland D.T., Warnock D.G., Muntner P. Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease. Am. J. Hypertens. 2012; 25(7): 789-796.
  37. Bolignano D., Palmer S.C., Navaneethan S.D., Strippoli G.F.M. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane database Syst. Rev. 2014; 4: CD007004.
  38. Bos H., Andersen S., Rossing P., De Zeeuw D., Parving H.H., De Jong P.E., Navis G. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int. Suppl. 2000; 75: S32-S37.
  39. Brenner B., Cooper M., Zeeuw D. de, Keane W., Mitch W.E., Parving H.-H., Snapinn S., Zhang Z., Shahinfar S. Effects oflosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
  40. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial. Int. 2007; 11(1): 21-31.
  41. Chobanian A., Bakris G., Black H. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560-2573.
  42. Clark W.F., Sontrop J.M., Macnab J.J., Suri R.S., Moist L., Salvadori M., Garg A.X. Urine volume and change in estimated GFR in a community-based cohort study. Clin. J. Am. Soc. Nephrol. 2011; 6(11): 2634-2641.
  43. Covic A., Goldsmith D. Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients. Nephrol. Dial. Transplant. 2002; 17(10): 1737-1741.
  44. Cushman W.C., Evans G.W., Byington R.P., Goff D.C., Grimm R.H., Cutler J.A., Simons-Morton D.G., Basile J.N., Corson M.A., Probstfield J.L., Katz L., Peterson K.A., Friedewald W.T., Buse J.B., Bigger J.T., Gerstein H.C., Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010; 362(17): 1575-1585.
  45. Dickinson H.O., Mason J.M., Nicolson D.J., Campbell F., Beyer F.R., Cook J.V., Williams B., Ford G.A. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J. Hypertens. 2006; 24(2): 215-233.
  46. Drawz P.E., Rosenberg M.E. Slowing progression of chronic kidney disease. Kidney Int. Suppl. 2013; 3(4): 372-376.
  47. Esnault V.L.M., Ekhlas A., Delcroix C., Moutel M.-G., Nguyen J.-M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J. Am. Soc. Nephrol. 2005; 16(2): 474-481. 48.
  48. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21(6): 1011-1053.
  49. Fine L.G., Norman J.T. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008; 74(7): 867-872.
  50. Foley R., Parfrey P., Sarnak M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32(5 Suppl 3): S112- S 119.
  51. Fouque D., Pelletier S., Mafra D., Chauveau P. Nutrition and chronic kidney disease. Kidney Int. 2011; 80(4): 348-357.
  52. Fox C.S., Matsushita K., Woodward M., Bilo H.J.G., Chalmers J., Heerspink H.J.L., Lee B.J., Perkins R.M., Rossing P., Sairenchi T., Tonelli M., Vassalotti J.A., Yamagishi K., Coresh J., de Jong P.E., Wen C.-P., Nelson R.G. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012; 380(9854): 1662-1673.
  53. Fried L.F., Emanuele N., Zhang J.H., Brophy M., Conner T. a, Duckworth W., Leehey D.J., McCullough P. a, O'Connor T., Palevsky P.M., Reilly R.F., Seliger S.L., Warren S.R., Watnick S., Peduzzi P., Guarino P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 2013; 369(20): 1892-1903.
  54. Fried L.F., Emanuele N., Zhang J.H., Brophy M., Conner T., Duckworth W., Leehey D.J., McCullough P., O'Connor T., Palevsky P.M., Reilly R.F., Seliger S.L., Warren S.R., Watnick S., Peduzzi P., Guarino P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 2013; 369(20): 1892-1903.
  55. Garneata L., Mircescu G. Effect of low-protein diet supplemented with keto acids on progression of chronic kidney disease. J. Ren. Nutr. 2013; 23(3): 210-213.
  56. Gisen T., Gruppo G., Epidemiologici S. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. 1997; 349: 1857-1863.
  57. Grassi G., Mancia G. New therapeutic approaches for resistant hypertension. J. Nephrol. 2012; 25(3): 276-281.
  58. Hallan S.I., Matsushita K., Sang Y., Mahmoodi B.K., Black C., Ishani A., Kleefstra N., Naimark D., Roderick P., Tonelli M., Wetzels J.F.M., Astor B.C., Gansevoort R.T., Levin A., Wen C.-P., Coresh J. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012; 308(22): 2349-2360.
  59. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., Ménard J., Rahn K.H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118): 1755-1762.
  60. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int. 2004; 66(1): 1-9. 61.
  61. Hörl W.H. Hypertension in end-stage renal disease: different measures and their prognostic significance. Nephrol. Dial. Transplant. 2010; 25(10): 3161-3166.
  62. Ikizler T.A., Cano N.J., Franch H., Fouque D., Himmelfarb J., Kalantar-Zadeh K., Kuhlmann M.K., Stenvinkel P., TerWee P., Teta D., Wang A.Y.-M., Wanner C. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. International Society of Nephrology. 2013; 84(6): 1096-1107. 63.
  63. Van Jaarsveld B.C., Krijnen P., Derkx F.H., Deinum J., Woittiez A.J., Postma C.T., Schalekamp M.A. Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens. J. Hum. Hypertens. 2001; 15(10): 669-676.
  64. Jafar T., Stark P., Schmid C., Landa M. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 2003; 139(4): 244-252.
  65. James P., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., Lackland D.T., Lefevre M.L., Mackenzie T.D., Ogedegbe O., Smith S.C., Svetkey L.P., Taler S.J., Townsend R.R., Wright J.T., Narva A.S., Ortiz E. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 1097: 1-14. 66.
  66. JATOS group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens. Res. 2008; 31(12): 2115-2127. 67.
  67. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013; (3(1)): 1-150. 68.
  68. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76(113): S1-S130. 69.
  69. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. Suppl. 2013; 3(3): 259-305. 70.
  70. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012; 2(4). 71.
  71. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2012; 2(5).
  72. Kim-Mitsuyama S., Ogawa H.M.K. An angiotensin II receptor blockercalcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than highdose angiotensin II receptor blockade alone. Kidney Int. 2013; 83: 167-176.
  73. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., Shulman N.B., Stamler J. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334(1): 13-18.
  74. Klahr S., Levey A.S., Beck G.J., Caggiula A.W., Hunsicker L., Kusek J.W., Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 1994; 330(13): 877-884.
  75. Kobori H., Nangaku M., Navar L.G., Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007; 59(3): 251-287.
  76. Ku E., Glidden D. V, Johansen K.L., Sarnak M., Tighiouart H., Grimes B., Hsu C.-Y. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int. 2015; 87(5): 1055-1060.
  77. Kuznik A., Mardekian J., Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. BMC Nephrol BMC Nephrology. 2013; 14(1): 132.
  78. Levey A., de Jong P., Coresh J., El Nahas M. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80: 17-28.
  79. Levin N.W., Kotanko P., Eckardt K.-U., Kasiske B.L., Chazot C., Cheung A.K., Redon J., Wheeler D.C., Zoccali C., London G.M. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2010; 77(4): 273-284.
  80. Lewis E., Hunsicker L., Clarke W., Berl T. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345(12): 851-860.
  81. Liu M., Takahashi H., Morita Y., Maruyama S., Mizuno M., Yuzawa Y., Watanabe M., Toriyama T., Kawahara H., Matsuo S. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol. Dial. Transplant. 2003; 18(3): 563-569.
  82. Ljutic D., Kes P. The role of arterial hypertension in the progression of nondiabetic glomerular diseases. Nephrol. Dial. Transplant. 2003; 18(5): v28-v30.
  83. Lotan Y., Daudon M., Bruyère F., Talaska G., Strippoli G., Johnson R.J., Tack I. Impact of fluid intake in the prevention of urinary system diseases: a brief review. Curr. Opin. Nephrol. Hypertens. 2013; 22(1): S1-S10.84.
  84. Lv J, Ehteshami P., Sarnak M.J., Tighiouart H., Jun M., Ninomiya T., Foote C., Rodgers A., Zhang H., Wang H., Strippoli G.F.M., Perkovic V. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013; 185(11): 949-957.
  85. Lv J., Neal B., Ehteshami P., Ninomiya T., Woodward M., Rodgers A., Wang H., MacMahon S., Turnbull F., Hillis G., Chalmers J., Perkovic V. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012; 9(8): e1001293.
  86. Mahmoodi B.K., Matsushita K., Woodward M., Blankestijn P.J., Cirillo M., Ohkubo T., Rossing P., Sarnak M.J., Stengel B., Yamagishi K., Yamashita K., Zhang L., Coresh J., de Jong P.E., Astor B.C. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012; 380(9854): 1649-1661. 87.
  87. MaioneA.,NavaneethanS.D., GrazianoG.,MitchellR.,JohnsonD.,MannJ.F.E., Gao P., Craig J.C., Tognoni G., Perkovic V., Nicolucci A., De Cosmo S., Sasso A., Lamacchia O., Cignarelli M., Manfreda V.M., Gentile G., Strippoli G.F.M. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol. Dial. Transplant. 2011; 26(9): 2827-2847.
  88. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J. Nilsson P.M., Ruilope L.M., Schmieder R.E.,Sirnes P.A.,Sleight P., Viigimaa M., Waeber B., Zannad F., Burnier M., Ambrosioni E., Caufield M., Coca A., Olsen M.H., Tsioufis C., van de Borne P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Ferrari R., Hasdai D., Hoes A.W., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Clement D.L., Gillebert T.C., Rosei E.A., Anker S.D., Bauersachs J., Hitij J.B., Caulfield M., De Buyzere M., De Geest S., Derumeaux G.A., Erdine S., Farsang C., Funck-Brentano C., Gerc V., Germano G., Gielen S., Haller H., Jordan J., Kahan T., Komajda M., Lovic D., Mahrholdt H., Ostergren J., Parati G., Perk J., Polonia J., Popescu B., Reiner Z, Rydén L., Sirenko Y., Stanton A., Struijker-Boudier H., Vlachopoulos C., Volpe M., Wood D. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.
  89. Mann J.F.E., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsärinne K., Oto A., Parkhomenko A., Piegas L.S., Svendsen T.L., Teo K.K., Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet. 2008; 372(9638): 547-553.
  90. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F.E., Motolese M., Ponticelli C., Ritz E., Zucchelli P. Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. N. Engl. J. Med. 1996; 334(15): 939-945.
  91. Nangaku M., Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens. Res. 2008; 31(2): 175-184. 92.
  92. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004; 43: S1-S290.
  93. Neymark E., LaBerge J.M., Hirose R., Melzer J.S., Kerlan R.K., Wilson M. W., Gordon R.L. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology. 2000; 214(3): 755-760.
  94. Nitsch D., Grams M., Sang Y., Black C., Cirillo M., Djurdjev O., Iseki K., Jassal S.K., Kimm H., Kronenberg F., Oien C.M., Levey A.S., Levin A., Woodward M., Hemmelgarn B.R. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a metaanalysis. BMJ. 2013; 346: f324.
  95. Ogihara T., Saruta T., Rakugi H., Matsuoka H., Shimamoto K., Shimada K., Imai Y., Kikuchi K., Ito S., Eto T., Kimura G., Imaizumi T., Takishita S., Ueshima H. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010; 56(2): 196-202.
  96. Parving H.-H., Brenner B.M., McMurray J.J. V, de Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Persson F., Nicolaides M., Richard A., Xiang Z., Armbrecht J., Pfeffer M. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J. Renin. Angiotensin. Aldosterone. Syst. 2012; 13(3): 387-393.
  97. Perna A., Ruggenenti P., Testa A., Spoto B., Benini R., Misefari V., Remuzzi G., Zoccali C. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int. 2000; 57: 274-281.
  98. Phillips C.O., Kashani A., Ko D.K., Francis G., Krumholz H.M. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch. Intern. Med. 2007; 167(18): 1930-1936.
  99. Pimenta E., Oparil S. Management of hypertension in the elderly. Nat. Rev. Cardiol. 2012; 9(5): 286-296.
  100. Qaseem A., Hopkins R.H., Sweet D.E., Starkey M., Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2013; 159(12): 835-847.
  101. Rao M.V, Qiu Y., Wang C., Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am. J. Kidney Dis. 2008; 51( 4): S30-S3 7.
  102. Ridao N., Luno J., Garcia de Vinuesa S., Gomez F., Tejedor a, Valderrábano F. Prevalence of hypertension in renal disease. Nephrol. Dial. Transplant. 2001; 16(1): 70-73.
  103. Rimoldi S.F., Scherrer U., Messerli F.H. Secondary arterial hypertension: when, who, and how to screen? Eur. Heart J. 2013; 35(19): 1245-1254.
  104. Robles N.R., Ocon J., Gomez C.F., Manjon M., Pastor L., Herrera J., Villatoro J., Calls J., Torrijos J., Rodriguez V.I., Rodriguez M.M.A., Mendez M.L., Morey A., Martinez F.I., Marco J., Liebana A., Rincon B., Tornero F. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
  105. Ruggenenti P., Perna A., Mosconi L., Matalone M., Pisoni R., Gaspari F., Remuzzi G. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The «Gruppo Italiano di Studi Epidemiologici in Nefrologia» (GISEN). Kidney Int. Suppl. 1997; 63: S54-S57.
  106. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G., Italiano G., Gisen N. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet. 1998; 352: 1252-1256.
  107. Ruggenenti P., Perna A., Loriga G., Ganeva M., Ene-Iordache B., Turturro M., Lesti M., Perticucci E., Chakarski I.N., Leonardis D., Garini G., Sessa A., Basile C., Alpa M., Scanziani R., Sorba G., Zoccali C., Remuzzi G. Bloodpressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005; 365(9463): 939-946.
  108. Ruggenenti P., Perna A., Remuzzi G., Dacco C. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 2001; 12(12): 2832-2837.
  109. Sarafidis P.A. Epidemiology of resistant hypertension. J. Clin. Hypertens. (Greenwich). 2011; 13(7): 523-528.
  110. Sarnak M.J., Greene T., Wang X., Beck G., Kusek J.W., Collins A.J., Levey A.S. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann. Intern. Med. 2005; 142(5): 342-351.
  111. Schrier R.W., Masoumi A., Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin. J. Am. Soc. Nephrol. 2010; 5(6): 1132-1140.
  112. Sim J.J., Bhandari S.K., Shi J., Reynolds K., Calhoun D.A., Kalantar-Zadeh K., Jacobsen S.J. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015; 6.
  113. Slagman M.C.J., Waanders F., Hemmelder M.H., Woittiez A.-J., Janssen W.M.T., Lambers Heerspink H.J., Navis G., Laverman G.D. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011; 343: d4366.
  114. Smith S.M. Epidemiology, prognosis, and treatment of resistant hypertension. Pharmacotherapy. 2013; 33(10): 1071-1086.
  115. Sontrop J.M., Dixon S.N., Garg A.X., Buendia-Jimenez I., Dohein O., Huang S.-H.S.,Clark W.F. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am. J. Nephrol. 2013; 37(5): 434-442.
  116. Taler S.J., Agarwal R., Bakris G.L., Flynn J.T., Nilsson P.M., Rahman M., Sanders P.W., Textor S.C., Weir M.R., Townsend R.R. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am. J. Kidney Dis. 2013; 62(2): 201-213.
  117. Turnbull F., Neal B., Ninomiya T., Algert C., Arima H., Barzi F., Bulpitt C., Chalmers J.,Fagard R., Gleason A.,Heritier S.,LiN.,Perkovic V., Woodward M., MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336(7653): 1121-1123. 118.
  118. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160): 703-713.
  119. Velez J.C.Q. The importance of the intrarenal renin-angiotensin system. Nat. Clin. Pract. Nephrol. 2009; 5(2): 89-100.
  120. Vogt L., Waanders F., Boomsma F., de Zeeuw D., Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 2008; 19(5): 999-1007.
  121. Wadei H.M., Textor S.C. The role of the kidney in regulating arterial blood pressure. Nat. Rev. Nephrol. 2012; 8(10): 602- 609.
  122. Weber M.A., Jamerson K., Bakris G.L., Weir M.R., Zappe D., Zhang Y., Dahlof B., Velazquez E.J., Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013; 381(9866): 537-545.
  123. Weber M., Schiffrin E.L., White W.B., Mann S., Lindholm L.H., Kenerson J.G., Flack J.M., Carter B.L., Materson B.J., Ram C.V.S., Cohen D.L., Cadet J.-C., Jean-Charles R.R., Taler S., Kountz D., Townsend R.R., Chalmers J., Ramirez A.J., Bakris G.L., Wang J., Schutte A.E., Bisognano J.D., Touyz R.M., Sica D., Harrap S.B. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International society of Hypertension. J. Clin. Hypertens. (Greenwich). 2014; 16(1): 14-26.
  124. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S., Sarnak M.J. The Framingham predictive instrument in chronic kidney disease. J. Am. Coll. Cardiol. 2007; 50(3): 217-224.
  125. Weiner D.E., Tighiouart H., Levey A.S., Elsayed E., Griffith J.L., Salem D.N., Sarnak M.J. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J. Am. Soc. Nephrol. 2007; 18(3): 960-966.
  126. Weir M.R. Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease. Clin. J. Am. Soc. Nephrol. 2009; 4(12): 2045-2050.
  127. White W.B., Turner J.R., Sica D.A., Bisognano J.D., Calhoun D.A., Townsend R.R., Aronow H.D., Bhatt D.L., Bakris G.L. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J. Am. Soc. Hypertens. 2014; 8(10): 743-757. 128.
  128. Wühl E., Trivelli A., Picca S., Litwin M., Peco-Antic A., Zurowska A., Testa S., Jankauskiene A., Emre S., Caldas-Afonso A., Anarat A., Niaudet P., Mir S., Bakkaloglu A., Enke B., Montini G., Wingen A.-M., Sallay P., Jeck N., Berg U., Caliskan S., Wygoda S., Hohbach-Hohenfellner K., Dusek J., Urasinski T., Arbeiter K., Neuhaus T., Gellermann J., Drozdz D., Fischbach M., Möller K., Wigger M., Peruzzi L., Mehls O., Schaefer F. Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med. 2009; 361(17): 1639-1650.
  129. Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 2009; 27(5): 923-934.
  130. Zhang Y., Zhang X., Liu L., Zanchetti A. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur. Heart J. 2011; 32(12): 1500-1508.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>